Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2019
The 9th European Lung Cancer Conference
Geneva, Switzerland - 10 Apr - 13 Apr 2019
Presentation Date(s):- 10 Apr - 13 Apr 2019
- Total Presentations: 489
-
+
State of art of TMB testing
- Type: Specialty session
- Presentations: 6
- Coordinates: 4/11/2019, 11:00 - 12:30, Room W
-
+
Session DOI
11:00 - 11:00
- Abstract
No abstract available for this presentation
-
+
TMB as predictor of immuno-oncology therapy: The science
11:00 - 11:20 | Presenter: David Robert Spigel
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
TMB testing in clinic
11:20 - 11:40 | Presenter: Jana Fassunke
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
TMB trumps PD-L1 as predictive biomarker for immuno-oncology therapy
11:40 - 12:00 | Presenter: Maurice Pérol
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PD-L1 is superior to TMB as predictive biomarker for immuno-oncology therapy
12:00 - 12:20 | Presenter: Fred R. Hirsch
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A / Panel Discussion
12:20 - 12:30
- Abstract
No abstract available for this presentation
-
+
The future of I-O in advanced NSCLC
- Type: Specialty session
- Presentations: 6
- Coordinates: 4/11/2019, 11:00 - 12:30, Room A
-
+
Session DOI
11:00 - 11:00
- Abstract
No abstract available for this presentation
-
+
Sequencing of I-O therapies
11:00 - 11:20 | Presenter: Sanjay Popat
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Progression on PD1/PD-L1 inhibitors: What is in the pipeline?
11:20 - 11:40 | Presenter: Stefan Zimmermann
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Cell-based I-O in NSCLC (TIL, TCRs, CARs, NK): Is there a role?
11:40 - 12:00 | Presenter: Joachim G Aerts
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Intratumoural I-O: A niche therapy?
12:00 - 12:20 | Presenter: Aurélien Marabelle
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A / Panel Discussion
12:20 - 12:30
- Abstract
No abstract available for this presentation
-
+
Lunch & Poster Display session
- Type: Poster Display session
- Presentations: 170
- Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
-
+
3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands
12:30 - 12:30 | Presenter: Chantal Epskamp-Kuijpers
- Abstract
Loading... -
+
4P - Correlation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma
12:30 - 12:30 | Presenter: Nobumasa Tamura
- Abstract
Loading... -
+
5P - The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma
12:30 - 12:30 | Presenter: Qi Huang
- Abstract
Loading... -
+
6P - Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer
12:30 - 12:30 | Presenter: Choonhee Son
- Abstract
Loading... -
+
7P - Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models
12:30 - 12:30 | Presenter: Uri Weinberg
- Abstract
Loading... -
+
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Marie Drosslerová
- Abstract
Loading... -
+
9P - Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer
12:30 - 12:30 | Presenter: Huijuan Ge
- Abstract
Loading... -
+
10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations
12:30 - 12:30 | Presenter: Wenxian Wang
- Abstract
Loading... -
+
11P - Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
12:30 - 12:30 | Presenter: lijun Liang
- Abstract
Loading... -
+
12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer
12:30 - 12:30 | Presenter: Quxia Zhang
- Abstract
Loading... -
+
13P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact
12:30 - 12:30 | Presenter: Rachel Shemesh
- Abstract
Loading... -
+
14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis
12:30 - 12:30 | Presenter: Youcai Zhu
- Abstract
Loading... -
+
15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor
12:30 - 12:30 | Presenter: Juan Felipe Cordoba Ortega
- Abstract
Loading... -
+
17P - REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors
12:30 - 12:30 | Presenter: Federico Pio Fabrizio
- Abstract
Loading... -
+
18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features
12:30 - 12:30 | Presenter: Eleni Kokkotou
- Abstract
Loading... -
+
19P - FOXP3Δ3, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer
12:30 - 12:30 | Presenter: Hao JIA
- Abstract
Loading... -
+
20P - Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice
12:30 - 12:30 | Presenter: Tian Fang Hou
- Abstract
Loading... -
+
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors
12:30 - 12:30 | Presenter: Daphne Dumoulin
- Abstract
Loading... -
+
23P - Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)
12:30 - 12:30 | Presenter: Roberto Ferrara
- Abstract
Loading... -
+
24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation
12:30 - 12:30 | Presenter: Paolo Manca
- Abstract
Loading... -
+
25P - Lung tumorspheres as a drug screening platform against cancer stem cells
12:30 - 12:30 | Presenter: Alejandro Herreros Pomares
- Abstract
Loading... -
+
26P - Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy
12:30 - 12:30 | Presenter: Laura Bonanno
- Abstract
Loading... -
+
27P - Comparison of three different gene panels for determination of tumor mutational burden by next generation sequencing
12:30 - 12:30 | Presenter: Roberto Pappesch
- Abstract
Loading... -
+
28P - Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients
12:30 - 12:30 | Presenter: Silvia Calabuig Fariñas
- Abstract
Loading... -
+
29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
12:30 - 12:30 | Presenter: Oscar Jose Juan Vidal
- Abstract
Loading... -
+
30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer
12:30 - 12:30 | Presenter: Ioannis Kotsantis
- Abstract
Loading... -
+
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
12:30 - 12:30 | Presenter: Joanna Domagala-Kulawik
- Abstract
Loading... -
+
32P - Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers
12:30 - 12:30 | Presenter: Elena Durendez-Saez
- Abstract
Loading... -
+
33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy
12:30 - 12:30 | Presenter: Kathrin Gennen
- Abstract
Loading... -
+
34P - Impacts of HDAC2 inhibition on lung cancer treatment
12:30 - 12:30 | Presenter: Yao-Tsung Yeh
- Abstract
Loading... -
+
35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population
12:30 - 12:30 | Presenter: YInchen Shen
- Abstract
Loading... -
+
36P - Can a BALF profile distinguish hot vs cold lung tumors?
12:30 - 12:30 | Presenter: Joanna Domagala-Kulawik
- Abstract
Loading... -
+
37P - Genetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals
12:30 - 12:30 | Presenter: Foteinos-Ioannis D. Dimitrakopoulos
- Abstract
Loading... -
+
38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells
12:30 - 12:30 | Presenter: Yichao Liu
- Abstract
Loading... -
+
39P - High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma
12:30 - 12:30 | Presenter: lijun Liang
- Abstract
Loading... -
+
40P - The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies
12:30 - 12:30 | Presenter: Ting-Chun Kuo
- Abstract
Loading... -
+
41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis
12:30 - 12:30 | Presenter: Caichen Li
- Abstract
Loading... -
+
44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative
12:30 - 12:30 | Presenter: Michael Snee
- Abstract
Loading... -
+
45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative
12:30 - 12:30 | Presenter: Marta Alexandra Silva Soares
- Abstract
Loading... -
+
46P - Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative
12:30 - 12:30 | Presenter: Jens Benn Sørensen
- Abstract
Loading... -
+
47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative
12:30 - 12:30 | Presenter: Simon Ekman
- Abstract
Loading... -
+
48P - Education and lung cancer: A Mendelian randomisation study
12:30 - 12:30 | Presenter: Huaqiang Zhou
- Abstract
Loading... -
+
49P - A Mendelian randomization study of the effects of Crohn’s disease on lung cancer
12:30 - 12:30 | Presenter: Jiaqing Liu
- Abstract
Loading... -
+
50P - Reduced-, and no-dose thin-section radiologic examinations: Comparison of capability for nodule detection in patients having pulmonary nodules
12:30 - 12:30 | Presenter: Wei Tang
- Abstract
Loading... -
+
51P - Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia
12:30 - 12:30 | Presenter: Katherine Mccann
- Abstract
Loading... -
+
52P - Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients
12:30 - 12:30 | Presenter: K. Adam Lee
- Abstract
Loading... -
+
53P - Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries
12:30 - 12:30 | Presenter: Mst Shamima Akter
- Abstract
Loading... -
+
56P - CT image standardization is superior to larger but heterogeneous data for robust radiomic models
12:30 - 12:30 | Presenter: Diem Vuong
- Abstract
Loading... -
+
57P - Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study
12:30 - 12:30 | Presenter: GUNDU NARESH
- Abstract
Loading... -
+
58P - Evaluation of a care path for patients with lung tumors and co-existing interstitial lung disease
12:30 - 12:30 | Presenter: Merle Ilona Ronden-Kianoush
- Abstract
Loading... -
+
59P - Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy
12:30 - 12:30 | Presenter: SABHEEN BUSHRA
- Abstract
Loading... -
+
60P - Nomogram for patients with stage I small cell lung cancer: A competing risk analysis
12:30 - 12:30 | Presenter: Jiaqing Liu
- Abstract
Loading... -
+
61P - Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model
12:30 - 12:30 | Presenter: Jing Yu
- Abstract
Loading... -
+
62P - External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy
12:30 - 12:30 | Presenter: Lukas Käsmann
- Abstract
Loading... -
+
63P - Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients
12:30 - 12:30 | Presenter: Maximilian Johannes Hochmair
- Abstract
Loading... -
+
64P - Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC)
12:30 - 12:30 | Presenter: Lynda M McSorley
- Abstract
Loading... -
+
65P - Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India
12:30 - 12:30 | Presenter: RANJEET RAM Jat
- Abstract
Loading... -
+
66P - Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice
12:30 - 12:30 | Presenter: Martin Sebastian
- Abstract
Loading... -
+
67TiP - ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer
12:30 - 12:30 | Presenter: Suresh Senan
- Abstract
Loading... -
+
73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
12:30 - 12:30 | Presenter: Ronald Damhuis
- Abstract
Loading... -
+
74P - Is there any prognostic significance of the level of change in SUVmax after SBRT in patients with early stage NSCLC?
12:30 - 12:30 | Presenter: Gokhan Yaprak
- Abstract
Loading... -
+
75P - Thoracic ultrasound can be a trustable tool in untouchable lung nodule surgery
12:30 - 12:30 | Presenter: Hongbin Zhang
- Abstract
Loading... -
+
76P - Endobronchial surgery and photodynamic therapy for early central lung cancer treatment
12:30 - 12:30 | Presenter: Sergey S Pirogov
- Abstract
Loading... -
+
77P - The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Matteo Gagliasso
- Abstract
Loading... -
+
78P - Lung resection for cancer in patients with heart disease: Management and postoperative outcome
12:30 - 12:30 | Presenter: Fatmir Spiro Caushi
- Abstract
Loading... -
+
79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer
12:30 - 12:30 | Presenter: Xiaohui Chen
- Abstract
Loading... -
+
80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Juan Felipe Cordoba Ortega
- Abstract
Loading... -
+
81P - Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer
12:30 - 12:30 | Presenter: Pedro Rocha
- Abstract
Loading... -
+
82TiP - IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy
12:30 - 12:30 | Presenter: Solange Peters
- Abstract
Loading... -
+
87P - Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
12:30 - 12:30 | Presenter: Arsela Prelaj
- Abstract
Loading... -
+
89P - Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark
12:30 - 12:30 | Presenter: Anders Green
- Abstract
Loading... -
+
90P - Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database
12:30 - 12:30 | Presenter: Nicolas Girard
- Abstract
Loading... -
+
91P - Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns
12:30 - 12:30 | Presenter: Fang Hu
- Abstract
Loading... -
+
92P - A prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC
12:30 - 12:30 | Presenter: SAIKAT Bhowal
- Abstract
Loading... -
+
93P - Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis
12:30 - 12:30 | Presenter: Julian Taugner
- Abstract
Loading... -
+
94P - Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience
12:30 - 12:30 | Presenter: Kaouther Harbegue
- Abstract
Loading... -
+
95P - The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC
12:30 - 12:30 | Presenter: Lukas Käsmann
- Abstract
Loading... -
+
96P - Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC
12:30 - 12:30 | Presenter: Michael Hoffmann
- Abstract
Loading... -
+
97P - Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy
12:30 - 12:30 | Presenter: Chukwuka Eze
- Abstract
Loading... -
+
98P - Implications for UK practice of the use of durvalumab in stage III NSCLC
12:30 - 12:30 | Presenter: Muhammad Shahid Iqbal
- Abstract
Loading... -
+
99P - Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence
12:30 - 12:30 | Presenter: Felipe Santa Rosa Roitberg
- Abstract
Loading... -
+
100P - A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy
12:30 - 12:30 | Presenter: Olarn Roengvoraphoj
- Abstract
Loading... -
+
101TiP - PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
12:30 - 12:30 | Presenter: Nicolas Girard
- Abstract
Loading... -
+
121P - Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
12:30 - 12:30 | Presenter: Julia Roeper
- Abstract
Loading... -
+
122P - Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts
12:30 - 12:30 | Presenter: James Chih-Hsin Yang
- Abstract
Loading... -
+
123P - Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China
12:30 - 12:30 | Presenter: Shuyuan Wang
- Abstract
Loading... -
+
124P - The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation
12:30 - 12:30 | Presenter: Jerry Li
- Abstract
Loading... -
+
125P - Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON
12:30 - 12:30 | Presenter: Wolfgang Brückl
- Abstract
Loading... -
+
126P - Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire
12:30 - 12:30 | Presenter: Darshan Sharma
- Abstract
Loading... -
+
127P - Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study
12:30 - 12:30 | Presenter: Zhen-Yu Ding
- Abstract
Loading... -
+
128P - Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer
12:30 - 12:30 | Presenter: mohamed lemine sow
- Abstract
Loading... -
+
129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer
12:30 - 12:30 | Presenter: Zengzhi Lian
- Abstract
Loading... -
+
130P - Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion
12:30 - 12:30 | Presenter: Jing Zhang
- Abstract
Loading... -
+
131P - Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
12:30 - 12:30 | Presenter: Changhui Li
- Abstract
Loading... -
+
132P - New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer
12:30 - 12:30 | Presenter: Jana Fassunke
- Abstract
Loading... -
+
133P - A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant
12:30 - 12:30 | Presenter: Jingjing Qu
- Abstract
Loading... -
+
134P - Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
12:30 - 12:30 | Presenter: Svenja Wagener
- Abstract
Loading... -
+
135P - EGFR & PD L1: An (im)perfect union
12:30 - 12:30 | Presenter: Ullas Batra
- Abstract
Loading... -
+
136P - Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience
12:30 - 12:30 | Presenter: Kristina Krpina
- Abstract
Loading... -
+
137P - Detection and clinicopathologic features of ctDNA in T790M-positive advanced lung adenocarcinomas patients after failure of treatment with first- and second-generation EGFR-TKIs
12:30 - 12:30 | Presenter: wei he
- Abstract
Loading... -
+
138P - PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype
12:30 - 12:30 | Presenter: Yang Zhang
- Abstract
Loading... -
+
139P - Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States
12:30 - 12:30 | Presenter: Xiaoyun Pan
- Abstract
Loading... -
+
140P - Brigatinib experience on the ALK project
12:30 - 12:30 | Presenter: Fabio Gomes
- Abstract
Loading... -
+
141P - Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)
12:30 - 12:30 | Presenter: Laura Angelats
- Abstract
Loading... -
+
142P - Clinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival
12:30 - 12:30 | Presenter: Bo Zhang
- Abstract
Loading... -
+
143P - Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study
12:30 - 12:30 | Presenter: Yiming Zhao
- Abstract
Loading... -
+
144P - Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs
12:30 - 12:30 | Presenter: Antonio Passaro
- Abstract
Loading... -
+
145P - Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients
12:30 - 12:30 | Presenter: Cleon Kho
- Abstract
Loading... -
+
146P - Clinical significance of ROS1 5’ deletions detected by FISH and response to crizotinib
12:30 - 12:30 | Presenter: Filippo Gustavo Dall'Olio
- Abstract
Loading... -
+
147P - Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Matthias Scheffler
- Abstract
Loading... -
+
148P - KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC
12:30 - 12:30 | Presenter: Marika Cinausero
- Abstract
Loading... -
+
149P - Efficacy of tyrosine kinase inhibitors (TKIs) in advanced lung adenosquamous carcinoma
12:30 - 12:30 | Presenter: Minjuan Hu
- Abstract
Loading... -
+
150P - Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy
12:30 - 12:30 | Presenter: Giulia Galli
- Abstract
Loading... -
+
151P - Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study
12:30 - 12:30 | Presenter: Hidehito Horinouchi
- Abstract
Loading... -
+
152P - Correlation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC
12:30 - 12:30 | Presenter: Letizia Gianoncelli
- Abstract
Loading... -
+
153P - Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis
12:30 - 12:30 | Presenter: Alfredo Addeo
- Abstract
Loading... -
+
154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy
12:30 - 12:30 | Presenter: Daphne Dumoulin
- Abstract
Loading... -
+
155P - Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Cristina Saavedra Serrano
- Abstract
Loading... -
+
156P - Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
12:30 - 12:30 | Presenter: Arsela Prelaj
- Abstract
Loading... -
+
157P - Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies
12:30 - 12:30 | Presenter: Anne Schett
- Abstract
Loading... -
+
158P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse
12:30 - 12:30 | Presenter: Alberto Pavan
- Abstract
Loading... -
+
159P - Initial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC
12:30 - 12:30 | Presenter: David Lang
- Abstract
Loading... -
+
160P - EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy
12:30 - 12:30 | Presenter: Arsela Prelaj
- Abstract
Loading... -
+
161P - Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
12:30 - 12:30 | Presenter: Philip Jermann
- Abstract
Loading... -
+
162P - Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC)
12:30 - 12:30 | Presenter: Vincenzo Pio Di Noia
- Abstract
Loading... -
+
163P - Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice
12:30 - 12:30 | Presenter: Martin Faehling
- Abstract
Loading... -
+
164P - PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC
12:30 - 12:30 | Presenter: Yi Qin
- Abstract
Loading... -
+
165P - Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis
12:30 - 12:30 | Presenter: Thierry Landre
- Abstract
Loading... -
+
166P - Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study
12:30 - 12:30 | Presenter: Konstantinos Rounis
- Abstract
Loading... -
+
167P - Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer
12:30 - 12:30 | Presenter: Bernardo L. Rapoport
- Abstract
Loading... -
+
168P - Dynamic changes of patelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC
12:30 - 12:30 | Presenter: Fei Zhou
- Abstract
Loading... -
+
169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)
12:30 - 12:30 | Presenter: Elena Corral de la Fuente
- Abstract
Loading... -
+
170P - Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade
12:30 - 12:30 | Presenter: Wei Nie
- Abstract
Loading... -
+
171P - Previous exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC
12:30 - 12:30 | Presenter: Fei Zhou
- Abstract
Loading... -
+
172P - A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer
12:30 - 12:30 | Presenter: Baohui Han
- Abstract
Loading... -
+
173P - Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival
12:30 - 12:30 | Presenter: Stephanie G.C. Kroeze
- Abstract
Loading... -
+
174P - NSCLC stages IIa-IIIc: Tumor related IGRT yields better local control than kV-guidance to anatomic structures
12:30 - 12:30 | Presenter: Franz Zehentmayr
- Abstract
Loading... -
+
175P - Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: MIREIA Martinez Kareaga
- Abstract
Loading... -
+
176P - Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy
12:30 - 12:30 | Presenter: Mattia Altini
- Abstract
Loading... -
+
177P - Real-world experience of ALK positive NSCLC from India
12:30 - 12:30 | Presenter: Mridul Malhotra
- Abstract
Loading... -
+
178P - Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients
12:30 - 12:30 | Presenter: Diana SY Abdulla
- Abstract
Loading... -
+
179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice
12:30 - 12:30 | Presenter: Martin Frueh
- Abstract
Loading... -
+
180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
12:30 - 12:30 | Presenter: James Spicer
- Abstract
Loading... -
+
181TiP - Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
12:30 - 12:30 | Presenter: Motostugu Shimokawa
- Abstract
Loading... -
+
182TiP - A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
12:30 - 12:30 | Presenter: Paul K. Paik
- Abstract
Loading... -
+
183TiP - A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
12:30 - 12:30 | Presenter: David Planchard
- Abstract
Loading... -
+
184TiP - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC
12:30 - 12:30 | Presenter: Lucia Nogova
- Abstract
Loading... -
+
185TiP - RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Luis Paz-Ares
- Abstract
Loading... -
+
186TiP - An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial
12:30 - 12:30 | Presenter: Francesco Gelsomino
- Abstract
Loading... -
+
187TiP - Tumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study
12:30 - 12:30 | Presenter: Uri Weinberg
- Abstract
Loading... -
+
188TiP - Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial
12:30 - 12:30 | Presenter: Giulia Galli
- Abstract
Loading... -
+
190P - ERGR-TKIs combined with chemotherapy delays intracranial progression in EGFR-mutant lung adenocarcinoma patients
12:30 - 12:30 | Presenter: Changhui Li
- Abstract
Loading... -
+
191P - Assessment of toxicity and clinical outcomes with SBRT in lung metastases: A single institute experience
12:30 - 12:30 | Presenter: Vibhay Pareek
- Abstract
Loading... -
+
192P - Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis
12:30 - 12:30 | Presenter: Agata Raniszewska
- Abstract
Loading... -
+
193P - Management of cN2 NSCLC patients treated with radical radiotherapy: Relapse with or without brain metastases
12:30 - 12:30 | Presenter: Fiona McKay
- Abstract
Loading... -
+
195TiP - Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Presenter: Minesh Mehta
- Abstract
Loading... -
+
197P - Effect of surgical treatment on the survival in patients with malignant pleural mesothelioma
12:30 - 12:30 | Presenter: Renata Baez-Saldana
- Abstract
Loading... -
+
198P - Efficacy of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro
12:30 - 12:30 | Presenter: Uri Weinberg
- Abstract
Loading... -
+
199P - Safety meta-analysis of clinical trials delivering TTFields to the upper torso
12:30 - 12:30 | Presenter: Giovanni Luca Ceresoli
- Abstract
Loading... -
+
200P - Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center
12:30 - 12:30 | Presenter: Konstantinos Leventakos
- Abstract
Loading... -
+
201P - Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience
12:30 - 12:30 | Presenter: SANJAY KUMAR GODARA
- Abstract
Loading... -
+
202P - Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape
12:30 - 12:30 | Presenter: Paul Naish
- Abstract
Loading... -
+
203P - Retrospective study about lung carcinoid: Our experience in a Spanish hospital
12:30 - 12:30 | Presenter: Dario SANCHEZ Sanchez Cabrero
- Abstract
Loading... -
+
204P - Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer
12:30 - 12:30 | Presenter: Sang Chul Lee
- Abstract
Loading... -
+
205P - Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor
12:30 - 12:30 | Presenter: Élia Cipriano
- Abstract
Loading... -
+
206P - Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center
12:30 - 12:30 | Presenter: IOANNA TSIOUPROU
- Abstract
Loading... -
+
207P - Primary mucinous carcinomas of the lung: Clinical characteristics and treatment outcomes
12:30 - 12:30 | Presenter: Antony George Francis Thottian
- Abstract
Loading... -
+
208P - Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis
12:30 - 12:30 | Presenter: Judith Büntzel
- Abstract
Loading... -
+
209P - Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study
12:30 - 12:30 | Presenter: Keisuke Kirita
- Abstract
Loading... -
+
210TiP - Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer
12:30 - 12:30 | Presenter: Antony George Francis Thottian
- Abstract
Loading...
-
+
MSD - Industry Satellite Symposium
- Type: Industry Satellite symposium
- Presentations: 5
- Coordinates: 4/11/2019, 13:00 - 14:00, Room A
-
+
Welcome and introduction
13:00 - 13:05 | Presenter: Natasha Leighl
- Abstract
No abstract available for this presentation
-
+
IO combinations in first-line NSCLC
13:05 - 13:20 | Presenter: Delvys Rodríguez-Abreu
- Abstract
No abstract available for this presentation
-
+
Role of monotherapy in first-line NSCLC
13:20 - 13:35 | Presenter: Natasha Leighl
- Abstract
No abstract available for this presentation
-
+
Patient profiles/cases
13:35 - 13:50 | Presenter: Stephen V Liu
- Abstract
No abstract available for this presentation
-
+
Q&A and Closing Remarks
13:50 - 14:00 | Presenter: Natasha Leighl
- Abstract
No abstract available for this presentation
-
+
Microbiome in cancer immunotherapy
- Type: Keynote Lecture
- Presentations: 2
- Coordinates: 4/11/2019, 14:10 - 14:40, Room B
-
+
Session DOI
14:10 - 14:10
- Abstract
No abstract available for this presentation
-
+
Microbiome in cancer immunotherapy
14:10 - 14:40 | Presenter: Laurence Zitvogel
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ESMO-IASLC Best Abstracts
- Type: Proffered Paper session
- Presentations: 7
- Coordinates: 4/11/2019, 14:45 - 16:15, Room B
-
+
Session DOI
14:45 - 14:45
- Abstract
No abstract available for this presentation
-
+
LBA1_PR - Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
14:45 - 15:00 | Presenter: Taofeek K Owonikoko
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
LBA3 - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
15:00 - 15:15 | Presenter: Byoung Chul Cho
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant LBA1_PR and LBA3
15:15 - 15:30 | Presenter: Luis Paz-Ares
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
102O - Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
15:30 - 15:45 | Presenter: Tony S.K. Mok
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
103O_PR - Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042
15:45 - 16:00 | Presenter: Kaname Nosaki
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 102O and 103O_PR
16:00 - 16:15 | Presenter: Sanjay Popat
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Management of side effects and toxicities
- Type: Educational session
- Presentations: 6
- Coordinates: 4/11/2019, 14:45 - 16:15, Room A
-
+
Session DOI
14:45 - 14:45
- Abstract
No abstract available for this presentation
-
+
Management of I-O toxicities: An introduction
14:45 - 15:00 | Presenter: Dolores Isla
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Management of pulmonary toxicities: Clinical case
15:00 - 15:15 | Presenter: Marina Chiara Garassino
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Management of endocrine toxicities: Clinical case
15:15 - 15:30 | Presenter: John B.A.G. Haanen
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Management of GI toxicities: Clinical case
15:30 - 15:45 | Presenter: Martin Sebastian
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A
15:45 - 16:15
- Abstract
No abstract available for this presentation
-
+
SCLC: What are the challenges and how can we face them?
- Type: Educational session
- Presentations: 6
- Coordinates: 4/11/2019, 14:45 - 16:15, Room C
-
+
Session DOI
14:45 - 14:45
- Abstract
No abstract available for this presentation
-
+
The pathologist’s point of view
14:45 - 15:05 | Presenter: Fernando Lopez-Rios
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
The medical oncologist’s point of view
15:05 - 15:25 | Presenter: Fiona Helen Blackhall
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
The radiation oncologist’s point of view
15:25 - 15:45 | Presenter: Cécile Le Pechoux
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
The surgeon´s point of view
15:45 - 16:05 | Presenter: Monica Casiraghi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A
16:05 - 16:15
- Abstract
No abstract available for this presentation
-
+
Coffee break
- Type: Coffee break
- Presentations: 0
- Coordinates: 4/11/2019, 16:15 - 16:45, Hall 1
-
+
Mini Oral session II
- Type: Mini Oral session
- Presentations: 9
- Coordinates: 4/11/2019, 16:40 - 17:40, Room C
-
+
Session DOI
16:40 - 16:40
- Abstract
No abstract available for this presentation
-
+
1O - Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma
16:40 - 16:45 | Presenter: Adam Januszewski
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
85O - Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)
16:45 - 16:50 | Presenter: David Planchard
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
116O - Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study
16:50 - 16:55 | Presenter: Maurice Pérol
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
117O - Racial disparities in characteristics and prognosis in Asian versus white patients receiving atezolizumab: An ancillary analysis of POPLAR and OAK studies
16:55 - 17:00 | Presenter: Jie Qian
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
118O - Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials
17:00 - 17:05 | Presenter: Wei Nie
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
119O - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO
17:05 - 17:10 | Author(s): Christian Grohe
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
189O - EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
17:10 - 17:15 | Presenter: Tao Jiang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion led by moderators
17:15 - 17:40
- Abstract
No abstract available for this presentation
first
prev
